Evaluation of Continuity of Care in Patients with mCRC – Baseline Characteristics of Participants in the PROMETCO Study
During this year's World Congress of the European Society for Medical Oncology (ESMO) on gastrointestinal malignancies, the baseline characteristics of participants in the ongoing PROMETCO study, which focuses on evaluating the continuity of care in patients with metastatic colorectal cancer (mCRC), were presented.
Clinical Study PROMETCO
At the end of June and beginning of July 2021, the ESMO World Congress focusing on current topics in gastrointestinal malignancies treatment took place in Barcelona, Spain. As part of the congress, a poster presentation from the ongoing PROMETCO study, aimed at evaluating the continuity of care in patients with metastatic colorectal cancer, was presented. The initial results of the study provide insight into the baseline biomolecular characteristics of patients.
Design
PROMETCO represents a prospective worldwide study from a real clinical setting. The planned study population is 1000 patients, with basic biomolecular characteristics of 277 patients included in the study so far being presented in the poster. The primary aim is to evaluate overall survival, while secondary aims include disease control as assessed by overall treatment response and patient quality of life.
Study Population
The average age at diagnosis in the study population is 66 years, which aligns with the age range of 56–67 years reported in a systematic review of 7 clinical studies. Left-sided tumors were more frequently diagnosed compared to right-sided tumors in the study population (44% vs. 28%) – this parameter also aligns with a subgroup analysis of 12 randomized studies. Rectal cancer was present in 28% of patients.
Routine molecular testing for RAS/BRAF mutations was performed on participating patients, with only 15% having an unknown status. On the other hand, molecular testing for microsatellite instability (MSI) was not commonly performed, with 50.9% of patients not having been tested, potentially impacting treatment selection and sequencing.
RAS mutations were diagnosed in 53% of patients (n = 146), BRAF mutations in 3% (n = 8). A non-mutant (wt) form of RAS/BRAF was found in 29% of patients (n = 81), and mutation status was unknown in 15% (n = 40). Regarding microsatellite instability, high and low instability were both observed in 0.7% of patients (n = 2 for each group), instability was not observed in 47.7% (n = 132), and more than half of the patients did not undergo instability testing (50.9%; n = 141).
Conclusion
The prospective PROMETCO study is still ongoing in the patient recruitment phase. The poster presented basic biomolecular characteristics of the patients involved so far, revealing that RAS/BRAF mutation testing is routine, while MSI testing was not conducted in more than half of the patients.
(holi)
Source: Koopman M., Pinto C., Bodoky G. Patient baseline characteristics in the PROMETCO study: a real-world, prospective longitudinal cohort on the continuum of care of metastatic colorectal cancer. Ann Oncol 2021 Jul 1; 32 (suppl. 3): S145–S146, doi: 10.1016/j.annonc.2021.05.192.
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
